Massachusetts General Hospital

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Martedì, Febbraio 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

Elicit Plant Announces the Appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)

Retrieved on: 
Giovedì, Marzo 7, 2024
Biotechnology, Other Health, Health, Other Natural Resources, Agriculture, Other Science, Natural Resources, Research, Environment, Science, Sustainability, Senior, Multimedia, Synthetic biology, Farmer, Growth, Hospital, Agtech, Colorado State University, Climate change, Patent, Intellectual property, Knowledge, Texas A&M University, Slavica, Massachusetts General Hospital, Harvard Medical School, CSO

Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).

Key Points: 
  • Elicit Plant, a pioneering and rapidly expanding agri-biotech company, announces the appointment of the renowned scientist and a leader in the ag-tech industry, Slavica Djonovic, Ph.D. as Chief Scientific Officer (CSO).
  • Elicit Plant's proprietary technology, EliTerra®, the consistent performance of its products internationally, and its team driven by a clear mission, are impressive," states Slavica Djonovic, CSO of Elicit Plant.
  • "In her new role as Chief Scientific Officer, Slavica will be tasked with amplifying Elicit Plant's scientific influence and accelerating the development of our EliTerra® Technological platform.
  • We are convinced that under her scientific leadership, Elicit Plant will reach a new milestone in developing innovative solutions for agriculture," concludes Jean-François Déchant, CEO of Elicit Plant.

Cancer Grand Challenges announces five new teams taking on cancer’s toughest challenges

Retrieved on: 
Mercoledì, Marzo 6, 2024
Research, Philanthropy, Fund Raising, General Health, Health, Foundation, Other Philanthropy, Science, Oncology, Other Science, Allergy, Massachusetts Institute of Technology, Incidence, Radiation, KITZ, NCI, PROTECT, Interdisciplinarity, Cancer Research UK, Prostate, Geography, National Cancer Institute, Breast, Neoplasm, Autoimmunity, University, KiKa, Death, Antigen, Patient, Factorization of polynomials, Disease, Massachusetts General Hospital, Grand Challenges, Risk, Mortality, Morehouse School of Medicine, Infection, Pharmaceutical industry

Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.

Key Points: 
  • Cancer Grand Challenges, a global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute, today announces funding for five new global research teams to take on some of the toughest cancer challenges: cancer inequities, early-onset cancers, solid tumors in children and T-cell receptors.
  • These include the Scientific Foundation of the Spanish Association Against Cancer, the Bowelbabe Fund for Cancer Research UK, Institut National Du Cancer, the Dutch Cancer Society, The Mark Foundation for Cancer Research and KiKa (Children Cancer Free Foundation).
  • “Together with our network of visionary partners and research leaders, Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines and aims to overcome cancer’s toughest problems,” said Dr. David Scott, Director of Cancer Grand Challenges.
  • The Cancer Grand Challenges community has grown to more than 1,200 investigators and collaborators with 16 teams from across the world taking on 13 challenges.

One Mind™ Accelerator Announces Second Cohort of Mental Health Startups

Retrieved on: 
Lunedì, Marzo 4, 2024
Mental Health, Health, Technology, Hospitals, Artificial Intelligence, Biotechnology, SMI, Suicide, AbbVie, Human, Pregnancy, Headway, Menopause, Alexandria Real Estate Equities, Diagnosis, Mental health, Bank, Pain, Soulside, Loneliness, Case management, Massachusetts General Hospital, Biology, GV (company), Anxiety, Woman, Mentorship, Health Care Service Corporation, Translation, PMS, DSM-IV codes, Speech, Bank of America, Collection, MD, Triage, Schizophrenia, Food, Boehringer Ingelheim, Death, Accelerator, Depression

One Mind™ , a leading mental health non-profit based in Napa Valley, CA, today announced the 2024 cohort of its flagship One Mind Accelerator program.

Key Points: 
  • One Mind™ , a leading mental health non-profit based in Napa Valley, CA, today announced the 2024 cohort of its flagship One Mind Accelerator program.
  • By supporting emerging companies through the Accelerator, One Mind seeks to positively impact the lives of people facing mental health challenges by advancing precision psychiatry, and making high quality mental healthcare more accessible, affordable, and equitable.
  • This is the second cohort for the One Mind Accelerator since the program’s launch in 2023.
  • Cerula Care is a virtual behavioral healthcare practice that partners with specialists and tailors behavioral health care for adults with serious illness.

Global Healthy Living Foundation Announces irAE Consortium to Address Immune-Related Adverse Events in Cancer Immunotherapy Patients

Retrieved on: 
Lunedì, Marzo 4, 2024
Oncology, Health, Managed Care, Research, Science, Biotechnology, Caregiver, MD, Immunotherapy, Consortium, Hope, Rheumatology, Patient, Duke University, Patient safety, MD Anderson Cancer Center, Medical Center, Massachusetts General Hospital, Cancer, Pharmaceutical industry

The nonprofit Global Healthy Living Foundation (GHLF) announced its collaboration as a co-founding member of the irAE Consortium, a newly formed collaborative effort uniting clinicians, researchers, and patients to tackle a critical issue facing cancer patients undergoing immunotherapy treatment: adverse reactions.

Key Points: 
  • The nonprofit Global Healthy Living Foundation (GHLF) announced its collaboration as a co-founding member of the irAE Consortium, a newly formed collaborative effort uniting clinicians, researchers, and patients to tackle a critical issue facing cancer patients undergoing immunotherapy treatment: adverse reactions.
  • The inaugural meeting of the Immune-Related Adverse Events (irAE) Consortium is scheduled for March 7-8, 2024, at the Cleveland Clinic in Ohio.
  • This initiative aims to address the unmet needs of cancer patients who experience adverse reactions to immunotherapy, a novel treatment approach.
  • Immunotherapy has revolutionized cancer treatment, offering new hope to patients by harnessing the body’s immune system to fight cancer.

Abridge Emerges as a Healthcare AI Leader, Raising $150M to Accelerate R&D

Retrieved on: 
Venerdì, Febbraio 23, 2024
Health, Technology, Hospitals, Health Technology, Software, General Health, Artificial Intelligence, EMR, Caregiver, Spark Capital, Artificial intelligence in healthcare, Multimedia, AI, Investment, Computer, Redpoint Ventures, Massachusetts General Hospital, Nuance Communications, Documentation, Series, Lightspeed Venture Partners, IVP, Associate, Patient, Speech, Union Square Ventures, Carnegie Mellon University, Research, Medical device

This raise comes just 4 months after their $30M Series B , and is one of the largest funding rounds made to date in generative AI for healthcare.

Key Points: 
  • This raise comes just 4 months after their $30M Series B , and is one of the largest funding rounds made to date in generative AI for healthcare.
  • Today, Abridge also announced a new enterprise agreement with the Yale New Haven Health System, the largest and most comprehensive healthcare system in Connecticut, that will give thousands of clinicians access to Abridge for clinical documentation.
  • Yale New Haven Health has selected Abridge as their generative AI partner in this area of ambient listening.
  • CTO Zack Lipton , a widely cited Associate Professor at Carnegie Mellon and pioneer in responsible AI research, has assembled the strongest research team in healthcare AI.

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
Giovedì, Febbraio 22, 2024
Health, Genetics, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Wake Forest University, Cambia Health Solutions, Senior, Doctor of Philosophy, RingCentral, Small business, Georgetown University, Medical director, Record, Molecular medicine, Drug development, Hospital, Radiology, Beyond Meat, MBA, MGH, Stanford University, University, Pathology, Associate, Patient, Intuit, Goldman Sachs, RPX, Massachusetts General Hospital, Harvard Medical School, Helmy Eltoukhy, Cancer, Management

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.

Lumicell Announces Initial Data Demonstrating LUMISIGHT™’s Ability to Detect Tumors Metastasized to Multiple Organs in the Peritoneum

Retrieved on: 
Martedì, Febbraio 20, 2024
Research, Medical Devices, Surgery, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, Oncology, Society, Survival, Massachusetts General Hospital, Peritoneum, Hospital, Optical flow, Peritoneal cavity, Surgical oncology, Associate, Patient, Dentistry

The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.

Key Points: 
  • The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum.
  • “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack.
  • “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer.
  • Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell.

FastWave Earns Third Utility Patent for Next-Generation IVL Technology

Retrieved on: 
Mercoledì, Marzo 6, 2024
IVL, Stenosis, Physician, Patent, Hospital, Disease, Associate, Health, Patient, Artery, Massachusetts General Hospital, Harvard Medical School, Mortality, Pharmaceutical industry

MINNEAPOLIS, March 6, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a clinical-stage medical device company developing differentiated intravascular lithotripsy (IVL) technology, announced the issuance of its third utility patent by the United States Patent and Trademark Office (USPTO). This latest patent – granted just three years from the company's inception – underscores FastWave's ambitious commitment to transforming the treatment of calcific artery disease.

Key Points: 
  • MINNEAPOLIS, March 6, 2024 /PRNewswire-PRWeb/ -- FastWave Medical, a clinical-stage medical device company developing differentiated intravascular lithotripsy (IVL) technology, announced the issuance of its third utility patent by the United States Patent and Trademark Office (USPTO).
  • "The issuance of FastWave's third utility patent is a testament to the phenomenal work being done by their experienced team.
  • By developing advanced lithotripsy platforms, FastWave aims to solve the gaps with existing IVL technology while improving ease of use and patient safety by reducing procedural complications.
  • Co-founder and CEO of FastWave Medical, Scott Nelson, emphasized the company's commitment to advancing IVL technology, stating, "We are thrilled to receive our third utility patent, which further validates the ingenuity of our IVL systems.

Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Venerdì, Marzo 1, 2024
Real-World Evidence, Massachusetts General Hospital, Spirometry, Data mart, ALS, Doctor of Philosophy, Interim analysis, Edaravone, M.S, Hospital, Conference, Natural history, State university system, Abstract, CDM, SVC, MDA, Phase 4, Episcopal conference, MTPA, Pharmaceutical industry

JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.

Key Points: 
  • JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
  • "These presentations reinforce our commitment to making a positive impact on the ALS community by better understanding disease markers and outcomes and providing important information on our treatment options for clinical practice."
  • Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study (James Berry, M.D., M.P.H.
  • Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis (Dung Pham, PhD; MTPA-CA)